Filewrapper

Supreme Court: patent licensee need not cease royalty payments to challenge patent’s vaildity

Today the Supreme Court decided MedImmune v. Genentech, a case about the power of federal courts to decide issues related to patent infringement and validity when one party to the dispute is currently licensing the patent from the other party. In an 8-1 decision, the Court held that a licensee need not stop paying royalties, […]

Continue Reading →

Speculation not required: IP litigation in 2006 produced $3.4 billion

Contrary to the statement in the previous post, apparently speculation is not required to determine the amount of money that changed hands as a result of intellectual property litigation in 2006. According to a survey [subscription required to view full story] by IP Law 360, intellectual property litigation resulted in a combined $3.4 billion in […]

Continue Reading →

Patent cases in 2006 result in over $1 billion in damages awarded

According to a study released by Bloomberg, United States juries in patent cases awarded a total of over $1 billion in damages in cases that went to jury trial in 2006, the largest single year ever. The largest award went to Rambus, a California maker of computer memory chips, who won a $307 million verdict […]

Continue Reading →

Working until the end of the year, Federal Circuit addresses a Law School Exam Type Case

The Federal Circuit affirmed a Southern District of Indiana decision that generic drug makers IVAX Pharmaceuticals, Inc, Dr. Reddy’s Labratories, Ltd. (DRL) and Teva Pharmaceuticals USA, Inc. infringed Eli Lilly and Company’s (Lilly) U.S. Patent no. 5,229,382. The ‘382 Patent claims chemical compound olanzapine and the use of the compound to treat schizophrenia. The infringers […]

Continue Reading →

New GAO report suggests that some patents may hamper development of new “innovative” drugs

A report released by the Government Accountability Office indicates that while expenditures on research and development by drug companies have increased, this has not resulted in a commensurate increase in new drug applications (NDAs) with the FDA. In fact, NDAs have decreased by 21% from 1999 to 2004. The larger concern raised by the report […]

Continue Reading →

Federal Circuit Addresses On Sale Bar

In Plumtree Software, Inc. v. Datamize, LLC, the Federal Circuit Court of Appeals revisited the issue of determining when an invention is on sale within the meaning of 35 U.S.C. 102(b). A claimed invention is considered to be on sale under ? 102(b) if the invention is sold or offered for sale more than one […]

Continue Reading →

UK considering peer review for patent system

After a review of Great Britain’s intellectual property laws, the UK patent office is considering implementing a peer review procedure as part of its patent examining process. This was one of the recommendations of the Gowers Review of Intellectual Property, published on December 6. The idea is based in part on the Peer to Patent […]

Continue Reading →

Federal Circuit considers intent required for inducing infringement en banc

The Federal Circuit resolved a perceived conflict in its case law regarding the necessary level of intent required for a defendant to be found liable for inducing infringement of a patent. The court considered one subsection of DSU Medical Corp. v. JMS Co. en banc to resolve the conflict. The court held that to prove […]

Continue Reading →

Nintendo hit with patent infringement lawsuit over “Wiimote”

Nintendo, makers of one of the hottest Christmas gifts this year, the Wii, is being sued for patent infringement. Interlink is suing the electronics giant over the "Wiimote," the common name for the Wii's controller. Below is the Wiimote and Figure 1 of Interlink's patent: Interlink's patent is directed toward a "trigger operated electronic device," […]

Continue Reading →

The problem of marketing an idea: how much do you tell a prospective licensee?

Forbes has an interesting piece regarding marketing ideas, specifically way to protect an idea when pitching it to companies or ways to avoid “giving something away” in the process. It’s written to be easily understood by non-lawyers, and has some good general suggestions. Notably absent from the list: using the line “I’d tell you, but […]

Continue Reading →

Stay in Touch

Receive the latest news and updates from us and our attorneys.

Sign Up